Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 08, 2016 01:00 ET | Source: Santhera Pharmaceuticals Holding AG

Swissmedic prüft Santheras Zulassungsantrag für Raxone® zur Behandlung von Duchenne-Muskeldystrophie

Liestal, Schweiz, 8. November 2016 - Santhera Pharmaceuticals (SIX: SANN) gibt bekannt, dass das Schweizerische Heilmittelinstitut (Swissmedic) Santheras Antrag auf Marktzulassung für Raxone®...
November 08, 2016 01:00 ET | Source: Santhera Pharmaceuticals Holding AG

Swissmedic Accepts for Review Santhera's Marketing Authorization Application for Raxone® for the Treatment of Duchenne Muscular Dystrophy

Liestal, Switzerland, November 8, 2016 - Santhera Pharmaceuticals (SIX: SANN) announces that the Swiss Agency for Therapeutic Products (Swissmedic) has accepted for review Santhera's Marketing...
October 04, 2016 01:00 ET | Source: Santhera Pharmaceuticals Holding AG

Santhera ernennt Kristina Timdahl zum Chief Medical Officer und Head of Development per Januar 2017

Liestal, Schweiz, 4. Oktober 2016 - Santhera Pharmaceuticals (SIX: SANN) gibt die Ernennung von Kristina Timdahl, MD, zum Chief Medical Officer (CMO) und Head of Development und Mitglied des...
October 04, 2016 01:00 ET | Source: Santhera Pharmaceuticals Holding AG

Santhera announces appointment of Kristina Timdahl as Chief Medical Officer and Head of Development as of January 2017

Liestal, Switzerland, October 4, 2016 - Santhera Pharmaceuticals (SIX: SANN) announces the appointment of Kristina Timdahl, MD, as Chief Medical Officer and Head of Development and Member of the...
September 28, 2016 01:00 ET | Source: Santhera Pharmaceuticals Holding AG

Santhera beginnt Phase-III-Studie (SIDEROS) mit Raxone bei Patienten mit Duchenne-Muskeldystrophie und gleichzeitiger Glucocorticoid-Behandlung

Liestal, Schweiz, 28. September 2016 - Santhera Pharmaceuticals (SIX: SANN) gibt bekannt, dass der erste Patient am University of Kansas Medical Center (KUMC), Department of Neurology, Kansas...
September 28, 2016 01:00 ET | Source: Santhera Pharmaceuticals Holding AG

Santhera Starts Phase III Study (SIDEROS) with Raxone in Patients with Duchenne Muscular Dystrophy Using Glucocorticoids

Liestal, Switzerland, September 28, 2016 - Santhera Pharmaceuticals (SIX: SANN) announces that the first patient has been enrolled at the University of Kansas Medical Center (KUMC), Department...
September 13, 2016 01:00 ET | Source: Santhera Pharmaceuticals Holding AG

Führendes medizinisches Fachjournal publiziert Wirksamkeit von Santheras Raxone auf die inspiratorische Atmungsfunktion bei Patienten mit Duchenne-Muskeldystrophie (DMD)

Liestal, Schweiz, 13. September 2016 - Santhera Pharmaceuticals (SIX: SANN) gibt bekannt, dass zusätzliche Daten aus der zulassungsrelevanten Phase-III-Studie (DELOS), welche die Wirksamkeit von...
September 13, 2016 01:00 ET | Source: Santhera Pharmaceuticals Holding AG

Leading medical journal publishes treatment effect of Santhera's Raxone on inspiratory function in patients with Duchenne muscular dystrophy (DMD)

Liestal, Switzerland, September 13, 2016 - Santhera Pharmaceuticals (SIX: SANN) announces that additional data from the pivotal phase III trial (DELOS) demonstrating efficacy of Raxone (idebenone)...
September 08, 2016 01:00 ET | Source: Santhera Pharmaceuticals Holding AG

Santhera's Idebenone (Raxone) erhält in Australien Orphan-Drug-Designation für Duchenne-Muskeldystrophie

Liestal, Schweiz, 8. September 2016 - Santhera Pharmaceuticals (SWX:SANN) gibt bekannt, dass die australische Zulassungsbehörde Therapeutic Goods Administration (TGA) Idebenone (Raxone) die...
September 08, 2016 01:00 ET | Source: Santhera Pharmaceuticals Holding AG

Santhera's Idebenone (Raxone) Receives Orphan Drug Designation for Duchenne Muscular Dystrophy in Australia

Liestal, Switzerland, September 8, 2016 - Santhera Pharmaceuticals (SWX: SANN), announces today that the Australian Therapeutic Goods Administration (TGA) has granted orphan drug designation (ODD)...